Role of Renin-Angiotensin System Blockade in Patients With Diabetes Mellitus

American Journal of Cardiology

Volumn 104, Issue 6, 2009, Pages 835-839

  Braga, Manoela F B ^a   Leiter, Lawrence A ^a,b  

^a ST MICHAEL'S HOSPITAL   (Canada)

^b UNIVERSITY OF TORONTO   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

CANDESARTAN; DIAMICRON MR; GLICLAZIDE; INDAPAMIDE PLUS PERINDOPRIL; LOSARTAN; NATEGLINIDE; PERINDOPRIL; QUINAPRIL; RAMIPRIL; RENIN ANGIOTENSIN SYSTEM BLOCKING AGENT; RENIN INHIBITOR; ROSIGLITAZONE; TELMISARTAN; UNCLASSIFIED DRUG; VALSARTAN;

CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CORONARY ARTERY DISEASE; DIABETES MELLITUS; DISEASE ASSOCIATION; HEART PROTECTION; HUMAN; HYPERTENSION; IMPAIRED GLUCOSE TOLERANCE; METABOLIC DISORDER; NEUROPATHY; PATHOGENESIS; PATHOPHYSIOLOGY; PRIORITY JOURNAL; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; REVIEW; RISK REDUCTION;

ANGIOTENSIN II TYPE 1 RECEPTOR BLOCKERS; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; DIABETES MELLITUS; DIABETES MELLITUS, TYPE 2; DISEASE PROGRESSION; ENDOTHELIUM, VASCULAR; HUMANS; RAMIPRIL; RENIN-ANGIOTENSIN SYSTEM; TETRAZOLES; THIAZOLIDINEDIONES; VALINE; VASODILATION; VENTRICULAR FUNCTION;

EID: 69549122918     PISSN: 00029149     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.amjcard.2009.05.015     Document Type: Review

References (35)

1. Chaturvedi N. The burden of diabetes and its complications: trends and implications for intervention. Diabetes Res Clin Pract 76 suppl (2007) S3-S12
2. American Diabetes Association. Standards of medical care in diabetes-2006. Diabetes Care 29 suppl (2006) S4-S42
3. Balkau B., Hu G., Qiao Q., Tuomilehto J., Borch-Johnsen K., and Pyörälä K. Prediction of the risk of cardiovascular mortality using a score that includes glucose as a risk factor. The DECODE Study. Diabetologia 47 (2004) 2118-2128
4. Cooper M.E. The role of the renin-angiotensin-aldosterone system in diabetes and its vascular complications. Am J Hypertens 17 (2004) 16S-20S
5. Jacob S., Rett K., and Henriksen E.J. Antihypertensive therapy and insulin sensitivity: do we have to redefine the role of beta-blocking agents?. Am J Hypertens 11 (1998) 1258-1265
6. Scheen A.J. CAPPP trial. Captopril Prevention Project. Lancet 353 (1999) 1793-1794
7. Yusuf S., Sleight P., Pogue J., Bosch J., Davies R., and Dagenais G.H.O.P.E.S.Investigators. Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. N Engl J Med 342 (2000) 145-153
8. ALLHAT Collaborative Research Group. Major cardiovascular events in hypertensive patients randomized to doxazosin vs chlorthalidone: the antihypertensive and lipid-lowering treatment to prevent heart attack trial (ALLHAT). JAMA 283 (2000) 1967-1975
9. Lindholm L.H., Ibsen H., Borch-Johnsen K., Olsen M.H., Wachtell K., Dahlöf B., Devereux R.B., Beevers G., de Faire U., Fyhrquist F., Julius S., Kjeldsen S.E., Kristianson K., Lederballe-Pedersen O., Nieminen M.S., Omvik P., Oparil S., Wedel H., Aurup P., Edelman J.M., and Snapinn S. Risk of new-onset diabetes in the Losartan Intervention for Endpoint Reduction in Hypertension study. J Hypertens 20 (2002) 1879-1886
10. Lithell H., Hansson L., Skoog I., Elmfeldt D., Hofman A., Olofsson B., Trenkwalder P., and Zanchetti A. The Study on Cognition and Prognosis in the Elderly (SCOPE): principal results of a randomized double-blind intervention trial. J Hypertens 21 (2003) 875-886
11. Kjeldsen S.E., Julius S., Mancia G., McInnes G.T., Hua T., Weber M.A., Coca A., Ekman S., Girerd X., Jamerson K., Larochelle P., MacDonald T.M., Schmieder R.E., Schork M.A., Stolt P., Viskoper R., Widimský J., and Zanchetti A. Effects of valsartan compared to amlodipine on preventing type 2 diabetes in high-risk hypertensive patients: the VALUE trial. J Hypertens 24 (2006) 1405-1412
12. Elliott W.J., and Meyer P.M. Incident diabetes in clinical trials of antihypertensive drugs: a network meta-analysis. Lancet 369 (2007) 201-207
13. Scheen A.J. Renin-angiotensin system inhibition prevents type 2 diabetes mellitus. Part 1. A meta-analysis of randomised clinical trials. Diabetes Metab 30 (2004) 487-496
14. Bosch J., Yusuf S., Gerstein H.C., Pogue J., Sheridan P., Dagenais G., Diaz R., Avezum A., Lanas F., Probstfield J., Fodor G., and Holman R.R. Effect of ramipril on the incidence of diabetes. N Engl J Med 355 (2006) 1551-1562
15. Califf R.M., Boolell M., Haffner S.M., Bethel M.A., McMurray J., Duggal A., and Holman R.R. Prevention of diabetes and cardiovascular disease in patients with impaired glucose tolerance: rationale and design of the Nateglinide and Valsartan in Impaired Glucose Tolerance Outcomes Research (NAVIGATOR) trial. Am Heart J 156 (2008) 623-632
16. Scheen A.J. Renin-angiotensin system inhibition prevents type 2 diabetes mellitus. Part 2. Overview of physiological and biochemical mechanisms. Diabetes Metab 30 (2004) 498-505
17. Leiter L.A., and Lewanczuk R.Z. Of the renin-angiotensin system and reactive oxygen species: Type 2 diabetes and angiotensin II inhibition. Am J Hypertens 18 (2005) 121-128
18. Erbe D.V., Gartrell K., Zhang Y.L., Suri V., Kirincich S.J., Will S., Perreault M., Wang S., and Tobin J.F. Molecular activation of PPARg by angiotensin II type 1-receptor antagonists. Vascul Pharmacol 45 (2006) 154-162
19. Yusuf S., Teo K., Anderson C., Pogue J., Dyal L., Copland I., Schumacher H., Dagenais G., and Sleight P. Effects of the angiotensin-receptor blocker telmisartan on cardiovascular events in high-risk patients intolerant to angiotensin-converting enzyme inhibitors: a randomised controlled trial. Lancet 372 (2008) 1174-1183
20. Tikellis C., Wookey P.J., Candido R., Andrikopoulos S., Thomas M.C., and Cooper M.E. Improved islet morphology after blockade of the renin- angiotensin system in the ZDF rat. Diabetes 53 (2004) 989-997
21. Sjølie A.K., Klein R., Porta M., Orchard T., Fuller J., Parving H.H., Bilous R., and Chaturvedi N. Effect of candesartan on progression and regression of retinopathy in type 2 diabetes (DIRECT-Protect 2): a randomised placebo-controlled trial. Lancet 372 (2008) 1385-1393
22. Patel A., MacMahon S., Chalmers J., Neal B., Woodward M., Billot L., Harrap S., Poulter N., Marre M., Cooper M., Glasziou P., Grobbee D.E., Hamet P., Heller S., Liu L.S., Mancia G., Mogensen C.E., Pan C.Y., Rodgers A., and Williams B. Effects of a fixed combination of perindopril and indapamide on macrovascular and microvascular outcomes in patients with type 2 diabetes mellitus (the ADVANCE trial): a randomised controlled trial. Lancet 370 (2007) 829-840
23. Bosch J., Lonn E., Pogue J., Arnold J.M., Dagenais G.R., and Yusuf S. Long-term effects of ramipril on cardiovascular events and on diabetes: results of the HOPE study extension. Circulation 112 (2005) 1339-1346
24. Daly C.A., Fox K.M., Remme W.J., Bertrand M.E., Ferrari R., and Simoons M.L. The effect of perindopril on cardiovascular morbidity and mortality in patients with diabetes in the EUROPA study: results from the PERSUADE substudy. Eur Heart J 26 (2005) 1369-1378
25. Carr A.A., Kowey P.R., Devereux R.B., Brenner B.M., Dahlof B., Ibsen H., Lindholm L.H., Lyle P.A., Snapinn S.M., Zhang Z., Edelman J.M., and Shahinfar S. Hospitalizations for new heart failure among subjects with diabetes mellitus in the RENAAL and LIFE studies. Am J Cardiol 96 (2005) 1530-1536
26. Didangelos T.P., Arsos G.A., Karamitsos D.T., Athyros V.G., Georga S.D., and Karatzas N.D. Effect of quinapril or losartan alone and in combination on left ventricular systolic and diastolic functions in asymptomatic patients with diabetic autonomic neuropathy. J Diabetes Complications 20 (2006) 1-7
27. Kawasaki D., Kosugi K., Waki H., Yamamoto K., Tsujino T., and Masuyama T. Role of activated renin-angiotensin system in myocardial fibrosis and left ventricular diastolic dysfunction in diabetic patients-reversal by chronic angiotensin II type 1A receptor blockade. Circ J 71 (2007) 524-529
28. Tropeano A.I., Boutouyrie P., Pannier B., Joannides R., Balkestein E., Katsahian S., Laloux B., Thuillez C., Struijker-Boudier H., and Laurent S. Brachial pressure-independent reduction in carotid stiffness after long-term angiotensin-converting enzyme inhibition in diabetic hypertensives. Hypertension 48 (2006) 80-86
29. Savoia C., Touyz R.M., Endemann D.H., Pu Q., Ko E.A., De Ciuceis C., and Schiffrin E.L. Angiotensin receptor blocker added to previous antihypertensive agents on arteries of diabetic hypertensive patients. Hypertension 48 (2006) 271-277
30. Savoia C., Touyz R.M., Volpe M., and Schiffrin E.L. Angiotensin type 2 receptor in resistance arteries of type 2 diabetic hypertensive patients. Hypertension 49 (2007) 341-346
31. Schiffrin E.L. Remodeling of resistance arteries in essential hypertension and effects of antihypertensive treatment. Am J Hypertens 17 (2004) 1192-1200
32. Karalliedde J., Smith A., DeAngelis L., Mirenda V., Kandra A., Botha J., Ferber P., and Viberti G. Valsartan improves arterial stiffness in type 2 diabetes independently of blood pressure lowering. Hypertension 51 (2008) 1617-1623
33. Maahs D.M., Snell-Bergeon J.K., Kinney G.L., Wadwa R.P., Garg S., Ogden L.G., and Rewers M. ACE-I/ARB treatment in type 1 diabetes patients with albuminuria is associated with lower odds of progression of coronary artery calcification. J Diabetes Complications 21 (2007) 273-279
34. Willemsen J.M., Westerink J.W., Dallinga-Thie G.M., van Zonneveld A.J., Gaillard C.A., Rabelink T.J., and de Koning E.J. Angiotensin II type 1 receptor blockade improves hyperglycemia-induced endothelial dysfunction and reduces proinflammatory cytokine release from leukocytes. J Cardiovasc Pharmacol 49 (2007) 6-12
35. Serebruany V.L., Pokov A.N., Malinin A.I., O'Connor C., Bhatt D.L., Tanguay J.F., Sane D.C., and Hennekens C.H. Valsartan inhibits platelet activity at different doses in mild to moderate hypertensives: Valsartan Inhibits Platelets (VIP) trial. Am Heart J 151 (2006) 92-99